Microsoft Acquiring Assets Of Merck Subsidiary Rosetta Biosoftware

Amit Chowdhry | Tuesday June 2, 2009 | 1,054 views| Add a Comment

rosetta-bio
Microsoft clearly has an expressed interest in the expansion of their life sciences division as indicated by the asset acquisition of Rosetta Biosoftware.  Rosetta is a subsidiary of Merck & Co., Inc.  Microsoft will be rolling Rosetta’s generic and data into their Amalga Life Sciences software.  Through the acquisition, Merck will become a customer of Amalga.

“This agreement establishes a stable and sustainable platform for the Rosetta Biosoftware technology,” stated Merck Research Laboratories VP Rupert Vessey.

The deal will most likely close at the end of this month and the combined technologies should be available sometime in early 2010.

[via CNET]

Related posts:

  1. Microsoft Acquiring Parlano As A Value-Add To Communications Software
  2. Microsoft Sells Off Shares In Comcast
  3. Microsoft Acquiring Advertising Company, aQuantive Inc. For $6 Billion
  4. Microsoft Acquiring Musiwave For Mobile Music Entertainment Purposes
  5. Report Indicates Yahoo! Was Planning To Turn Down Google Ad Outsourcing, One Day Before The Microsoft Bid


If you loved this post, "Like" us on Facebook!

This website uses IntenseDebate comments, but they are not currently loaded because either your browser doesn't support JavaScript, or they didn't load fast enough.

Copyright 2011 Pulse 2, LLC | About | Privacy Statement